Senate Hearing: Impact of Offshoring Biotech Manufacturing to China and IRA on US Investment

Biotech Investment and Offshoring

• 💡 Biotechnology development and manufacturing in the US is important, and there's a movement of companies, investment, and manufacturing to China.
• ⚠️ Efforts are needed to encourage the return of this manufacturing back to the US.

Impact of the IRA on Biotech

• 📉 The Inflation Reduction Act (IRA) is a factor affecting emerging biotechnology, though its precise impact on funded programs is hard to quantify.
• 🔬 In the near term, R&D programs continue to be funded, but there are concerns about the long-term impact of the IRA.
• 📊 A shift is observed from small molecules to large molecules in research funding due to the IRA, potentially not following the science, especially since small molecules are crucial for crossing the blood-brain barrier.

Challenges in Domestic Manufacturing

• 🏭 The closure of a generic drug plant in Shreveport, where manufacturing moved to India, highlights the challenge of lower labor costs abroad.
• 💰 The upfront cost of investing in advanced manufacturing and robotics can be prohibitive, making it difficult to compete with lower costs in countries like India.
• 📈 Even with upfront investment and amortization over 20 years, the low margins on many generic products make domestic manufacturing unprofitable.

FDA and CMS Approval Processes

• ⏳ There are substantial time delays, approximately 5.7 years, between FDA approval (safety and efficacy) and insurance coverage (reasonable and necessary).
• ❓ The standard of "reasonable and necessary" is unclear and not well-defined, unlike the FDA's safety and efficacy standards.
• 🧩 This creates a Byzantine and long process, delaying investor funding and market access for innovations.

Third-Party Review and Evidence Quality

• 📉 The third-party review pathway for medical devices is underutilized (around 2%), partly due to variable quality of reviews.
• ⚠️ Government audits have shown discrepancies in vendor quality, forcing the FDA to re-review, diminishing the incentive for third-party reviews.
• 🔬 A significant issue is the quality of pre-market evidence, with about one in ten breakthrough devices lacking clinical testing for safety and efficacy.
• 📊 Many breakthrough devices also lack post-market requirements to confirm safety and efficacy.
• ⚠️ For Medicare, "reasonable and necessary" also means for beneficiaries, including older adults, who are often underrepresented in clinical trials, complicating Medicare coverage decisions.

Potential Reforms and AI

• 🚀 Legislation in Congress aims for accelerated coverage and companion studies to address these questions.
• 🤖 AI could be exceptionally helpful in reforming these processes and addressing delays.
• ✅ There is a need for process reform within the FDA and CMS systems.